Johnson & Johnson JNJ

$267.14 -5.56 (-2.04%)

Valuation

Market cap
656,473,472,000
Revenue TTM
$94,193,000,000
Net income TTM
$26,804,000,000
P/E (trailing)
26.17
P/E (forward)
25.07
Profit margin
28.46%
Debt to equity
0.44

Trading

Volume
9,842,200
Avg volume
7,466,768
Day's range
$264.68 – $270.60
Shares out
2,407,310,000
Stochastic %K
10%
Beta
0.22
Analysts
Moderate Buy
Price target
$283.64

Price

Company profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular...

Show more

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
732 524 0400
Website
https://www.jnj.com
Address
One Johnson & Johnson Plaza, New Brunswick, United States

Latest news

Stocktwits

viji998 Nov 20, 5:28 AM
$NBIS every freaking $WMT $JNJ $JPM or take any sector depends on data , so data to be processed via AI models they need more and more capacity people who don’t have basic knowledge they just spread the rumors to make others to believe more like shorts 🩳
0 replies
itsallaboutheoptions Nov 20, 4:29 AM
All About The Options 4h delay $JNJ News: Johnson & Johnson's $3.05 billion acquisition of Halda Therapeutics is showing promise as JNJ-6143 demonstrated excellent results in early-stage prostate cancer trials, with a 75% overall response rate in heavily pre-treated patients - real time news access https://itsallaboutheoptions.com/dashboard
0 replies
Suite510 Nov 19, 11:49 PM
$JNJ $SPX Lawyers for shareholders say they are preparing for trial J&J estimated potential damages exceed $10 billion in Supreme Court filing. Lanier represented women who sued J&J over talc products ooops 😅
0 replies
Suite510 Nov 19, 11:47 PM
$JNJ $SPX oh look only 10 Billion out the window 🪟 😂
0 replies
Suite510 Nov 19, 11:39 PM
$JNJ $SPX More Xmas fun 🙈🎁 California Jury Awards $34.2 Million in Johnson & Johnson Talc Lawsuit Written by Tara Strand on November 19, 2026
0 replies
GridironGainz Nov 19, 9:36 PM 0 replies
GridironGainz Nov 19, 8:55 PM 0 replies
cuemark8 Nov 19, 8:46 PM
$JNJ About this time this overinflated stock tumbles. Take this back to 200 and I'll buy. I think just about every stock out there will test new 52 week lows soon .
0 replies